Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (22)

2023

  1. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  2. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2020

  1. Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 373-377

  2. Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 6, pp. 1299-1306

  3. Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis

    Medicina Clinica, Vol. 155, Núm. 5, pp. 220.e1-220.e12

2019

  1. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  3. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

2018

  1. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96

  2. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

    Ophthalmology, Vol. 125, Núm. 9, pp. 1444-1451

2017

  1. Development of an activity disease score in patients with uveitis (UVEDAI)

    Rheumatology International, Vol. 37, Núm. 4, pp. 647-656

  2. Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis

    Medicine (United States), Vol. 96, Núm. 42

  3. The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review

    Seminars in Arthritis and Rheumatism, Vol. 46, Núm. 5, pp. 569-583

  4. Treatment recommendations for non-infectious anterior uveitis

    Medicina Clinica, Vol. 149, Núm. 12, pp. 552.e1-552.e12

2016

  1. Multidisciplinary dermatology–rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review

    Rheumatology International, Vol. 36, Núm. 2, pp. 221-229

  2. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

2014

  1. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis

    Pharmacogenomics, Vol. 15, Núm. 14, pp. 1763-1769

  2. The emerging problem of biological treatment in migrant and travelling populations: It is time to extend guidelines for the screening of infectious diseases

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 5, pp. 794-796

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557